COPD and Cardiovascular Risk in the Population (CORSAIB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00787748
Recruitment Status : Completed
First Posted : November 7, 2008
Last Update Posted : June 15, 2012
Fondo de Investigacion Sanitaria
Information provided by (Responsible Party):

Brief Summary:

The prevalence of chronic obstructive pulmonary disease (COPD) in patients with cardiovascular disease (CVD) is unknown, and whether or not COPD is adequately diagnosed and treated in these patients has not been investigated before.

We hypothesized that the prevalence of COPD would be significantly higher (30%) in patients with CVD than in the general population. Besides, we anticipated that COPD, a potentially treatable CV risk factor, would be undiagnosed in more than 80% of CVD patients.

Condition or disease
Chronic Obstructive Pulmonary Disease Cardiovascular Disease

Detailed Description:

We aim to compare clinical and spirometric data in three groups of individuals. Two of them are participants in an ongoing population-based study (CORSAIB) aimed at investigating the distribution of CVD risk factors in the general population of the Balearic Islands, Spain. The design and full methodological details of the CORSAIB study have been published elsewhere (Rigo F, et al. Rev Clin Espa 2005). A third group will include patients with stable CVD regularly visited at the referral hospital of our community.

Inclusion criteria for the study are male and female individuals, aged 40 to 81 years, residents of the Balearic Islands, and who are willing to participate in this research.

Study Type : Observational
Actual Enrollment : 623 participants
Time Perspective: Cross-Sectional
Official Title: COPD and Cardiovascular Risk in the Population
Study Start Date : October 2006
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Primary Outcome Measures :
  1. Prevalence of COPD defined according to the current GOLD guidelines as a post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) <0.7. [ Time Frame: Current ]

Secondary Outcome Measures :
  1. Underdiagnosis of COPD [ Time Frame: Current ]
  2. Undertreatment of COPD [ Time Frame: Current ]

Biospecimen Retention:   Samples Without DNA
Samples of serum were frozen at -80 ºC

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 81 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Random population sample, and a sample of hospital cardiovascular patients

Inclusion Criteria:

  • residents of the Balearic Islands
  • willing to participate in this research
  • able to sign the written consent form

Exclusion Criteria:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00787748

Bunola, Illes Balears, Spain, 07110
Sponsors and Collaborators
Fondo de Investigacion Sanitaria
Study Director: Fernando Rigo, MD Atención Primaria de Mallorca
Study Director: Alvar Agusti, MD Cimera

Additional Information:
Publications of Results:
Responsible Party: Cimera Identifier: NCT00787748     History of Changes
Other Study ID Numbers: PI061228
First Posted: November 7, 2008    Key Record Dates
Last Update Posted: June 15, 2012
Last Verified: June 2012

Keywords provided by Cimera:

Additional relevant MeSH terms:
Lung Diseases
Cardiovascular Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases